DUBLIN, September 15, 2016 /PRNewswire/ --
Research and Markets has announced the addition of the "Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes" drug pipelines to their offering.
Although opioids continue to dominate the chronic pain market, adverse events associated with the drug such as the potential for abuse mean the treatment space is rife with unmet needs, which is encouraging pharmaceutical companies to explore innovative alternatives to opioids.
Our latest report states that while opioids remain the most effective modes of treatment, their potential for abuse has yet to be addressed, and thus their effectiveness is limited in chronic pain conditions, as they cannot be used for prolonged durations.
One of the publishers analysts states that: Moderate-to-severe pain has been and continues to be dominated by opioids, which are increasingly being reformulated to offer abuse resistance, whereas mild pain is effectively being treated with non-steroidal anti-inflammatory drugs (NSAID).
However, significant unmet needs remain, as chronic pain subtypes - and particularly neuropathic pain - often do not respond well to existing therapies, which do not align well with the underlying molecular pathophysiological causes of pain.
While the pain therapeutics pipeline is extremely large and diverse, it is characterized by a high overall historic clinical attrition rate for novel analgesics, and a low level of first-in-class innovation.
The active pain pipeline is populated by 810 products across all stages of development, which exhibit a highly diverse range of molecular targets. GBI Research's analyses identified 129 first-in-class programs in active development, constituting 20% of the pipeline for which there is a disclosed molecular target, and acting on 80 first-in-class molecular targets.
Key Topics Covered:
1 Tables & Figures
2 Executive Summary
2.1 Substantial Unmet Needs Remain in Core Therapy Types
2.2 Highly Diversified Range of Innovative Programs in Early Pipeline
2.3 Rich Pipeline Landscape with Numerous Investment Opportunities
3 The Case for Innovation
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Development Remains Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation
3.6 Research Report Guidance
4 Clinical and Commercial Landscape
5 Assessment of Pipeline Product Innovation in Chronic, Acute and Neuropathic Pain
5.1 Pain Pipeline by Molecule Type, Stage of Development and Molecular Target
5.2 Comparative Distribution of Programs between the Pain Market and Pipeline by Therapeutic Target Family
5.3 First-in-Class Pipeline Programs
5.4 First-in-Class and Established Pipeline Products by Pain Subtype
5.5 Table of All First-in-Class Pain Pipeline Products
6 Pain Pathophysiology and Innovation Alignment
6.1 The Complexity of Signaling Networks in the Central Nervous System
6.2 Matrix Assessment
7 First-in-Class Target and Pipeline Program Evaluation
7.1 Pipeline Programs Targeting Nerve Growth Factor and High Affinity Nerve Growth Factor Receptor
7.2 Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 16
7.3 Pipeline Programs Targeting Bradykinin B1 Receptor
7.4 Pipeline Programs Targeting Opioid Receptor-Like-1 Receptor
7.5 Pipeline Programs Targeting Purinoceptor 7
7.6 Pipeline Programs Targeting Metabotropic Glutamate Receptors 6 and 7
7.7 Pipeline Programs Targeting Calcitonin Gene-Related Peptide Type-1 Receptor
8 Deals and Strategic Consolidations
8.1 Industry-Wide First-in-Class Deals
8.2 Pain Deals Landscape
8.3 Licensing Deals
8.4 Co-development Deals
8.5 List of Pipeline Products without Prior Licensing or Co-Development Deal Involvement
For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/ksjzjc/frontier_pharma
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/chronic-acute-and-neuropathic-pain-market-report-2016---chronic-pain-treatment-pipeline-could-yield-innovative-alternatives-to-opioids---research-and-markets-300328680.html
SOURCE Research and Markets